Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T
The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in an ongoing trial.
Previous Post
Staying level: what you need to know about your lab balance
Next Post
Johnny Cheng appointed as interim CEO of HUTCHMED
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago